Published in Nat Med on September 04, 2011
Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog (2012) 2.87
A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis (Edinb) (2013) 2.10
Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset. PLoS Pathog (2013) 1.54
Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin Vaccine Immunol (2011) 1.15
B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog (2013) 1.14
Mycobacterium tuberculosis type VII secreted effector EsxH targets host ESCRT to impair trafficking. PLoS Pathog (2013) 1.10
The ins and outs of Mycobacterium tuberculosis protein export. Tuberculosis (Edinb) (2011) 1.06
Vaccine development for tuberculosis: current progress. Drugs (2013) 1.01
Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model. PLoS One (2014) 0.98
The ESX-3 secretion system is necessary for iron and zinc homeostasis in Mycobacterium tuberculosis. PLoS One (2013) 0.97
Mycobacterium tuberculosis directs T helper 2 cell differentiation by inducing interleukin-1β production in dendritic cells. J Biol Chem (2012) 0.95
Structure of the mycosin-1 protease from the mycobacterial ESX-1 protein type VII secretion system. J Biol Chem (2013) 0.94
Mycobacterial Esx-3 requires multiple components for iron acquisition. MBio (2014) 0.93
Separable roles for Mycobacterium tuberculosis ESX-3 effectors in iron acquisition and virulence. Proc Natl Acad Sci U S A (2016) 0.93
Protection versus pathology in tuberculosis: recent insights. Curr Opin Immunol (2012) 0.92
Current and novel approaches to vaccine development against tuberculosis. Front Cell Infect Microbiol (2012) 0.91
Prime-boost approaches to tuberculosis vaccine development. Expert Rev Vaccines (2012) 0.91
ESX secretion systems: mycobacterial evolution to counter host immunity. Nat Rev Microbiol (2016) 0.91
Noncanonical SMC protein in Mycobacterium smegmatis restricts maintenance of Mycobacterium fortuitum plasmids. Proc Natl Acad Sci U S A (2014) 0.90
Exosomes carrying mycobacterial antigens can protect mice against Mycobacterium tuberculosis infection. Eur J Immunol (2013) 0.90
The next 10 years for tuberculosis vaccines: do we have the right plans in place? Expert Rev Vaccines (2013) 0.90
Novel vaccine approaches for protection against intracellular pathogens. Curr Opin Immunol (2014) 0.89
Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice. PLoS One (2013) 0.89
Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis. J Biol Chem (2014) 0.87
Identifying feasible metabolic routes in Mycobacterium smegmatis and possible alterations under diverse nutrient conditions. BMC Microbiol (2014) 0.87
Computational genomics-proteomics and Phylogeny analysis of twenty one mycobacterial genomes (Tuberculosis & non Tuberculosis strains). Microb Inform Exp (2012) 0.86
Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis. PLoS One (2013) 0.86
Permutations of time and place in tuberculosis. Lancet Infect Dis (2015) 0.83
CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease. PLoS Pathog (2016) 0.83
Comparison of the membrane proteome of virulent Mycobacterium tuberculosis and the attenuated Mycobacterium bovis BCG vaccine strain by label-free quantitative proteomics. J Proteome Res (2013) 0.82
Aging-related anatomical and biochemical changes in lymphatic collectors impair lymph transport, fluid homeostasis, and pathogen clearance. Aging Cell (2015) 0.81
Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice. PLoS One (2012) 0.81
Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis. J Biol Chem (2014) 0.81
Tuberculosis vaccine types and timings. Clin Vaccine Immunol (2014) 0.81
Isoniazid induces apoptosis of activated CD4+ T cells: implications for post-therapy tuberculosis reactivation and reinfection. J Biol Chem (2014) 0.81
Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy. Nat Commun (2016) 0.79
Mycobacterium tuberculosis TlyA Protein Negatively Regulates T Helper (Th) 1 and Th17 Differentiation and Promotes Tuberculosis Pathogenesis. J Biol Chem (2015) 0.78
Tuberculosis vaccine promises sterilizing immunity. Nat Med (2011) 0.78
CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection. PLoS Pathog (2016) 0.77
Vaccines: Protecting against tuberculosis. Nat Rev Drug Discov (2011) 0.77
Differential Immune Responses and Protective Effects in Avirulent Mycobacterial Strains Vaccinated BALB/c Mice. Curr Microbiol (2015) 0.77
Vaccines for TB: Lessons from the Past Translating into Future Potentials. J Immunol Res (2015) 0.76
A novel genetically engineered Mycobacterium smegmatis-based vaccine promotes anti-TB immunity. Expert Rev Vaccines (2012) 0.76
Autophagy-Related Proteins Target Ubiquitin-Free Mycobacterial Compartment to Promote Killing in Macrophages. Front Cell Infect Microbiol (2016) 0.76
Mycobacterium tuberculosis EsxH inhibits ESCRT-dependent CD4(+) T-cell activation. Nat Microbiol (2016) 0.76
Enhanced priming of adaptive immunity by Mycobacterium smegmatis mutants with high-level protein secretion. Clin Vaccine Immunol (2012) 0.76
Retracted A β-Lactamase based reporter system for ESX dependent protein translocation in mycobacteria. PLoS One (2012) 0.76
Current efforts and future prospects in the development of live mycobacteria as vaccines. Expert Rev Vaccines (2015) 0.76
Profile of William R. Jacobs, Jr. Proc Natl Acad Sci U S A (2014) 0.75
Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination. Front Immunol (2016) 0.75
Recombinant Mycobacterium smegmatis with a pMyong2 vector expressing Human Immunodeficiency Virus Type I Gag can induce enhanced virus-specific immune responses. Sci Rep (2017) 0.75
Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection. Hum Vaccin Immunother (2016) 0.75
Mycobacterium avium MAV2054 protein induces macrophage apoptosis by targeting mitochondria and reduces intracellular bacterial growth. Sci Rep (2016) 0.75
Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophages. Appl Environ Microbiol (2012) 0.75
Role of Metal-Dependent Regulation of ESX-3 Secretion in Intracellular Survival of Mycobacterium tuberculosis. Infect Immun (2016) 0.75
[Experimental vaccination against tuberculosis]. Pharm Unserer Zeit (2012) 0.75
The Phytochemical Bergenin Enhances T Helper 1 Responses and Anti-Mycobacterial Immunity by Activating the MAP Kinase Pathway in Macrophages. Front Cell Infect Microbiol (2017) 0.75
Immunogenicity of a recombinant Mycobacterium smegmatis vaccine expressing the fusion protein CMX in cattle from Goiás State, Brazil. J Vet Med Sci (2014) 0.75
Intranasal Administration of Recombinant Mycobacterium smegmatis Inducing IL-17A Autoantibody Attenuates Airway Inflammation in a Murine Model of Allergic Asthma. PLoS One (2016) 0.75
Overexpression of RORγt Enhances Pulmonary Inflammation after Infection with Mycobacterium Avium. PLoS One (2016) 0.75
Identification of mycobacterial RplJ/L10 and RpsA/S1 proteins as novel targets for CD4+ T cells. Infect Immun (2017) 0.75
Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis. Sci Rep (2017) 0.75
Transcriptome Analysis of Mycobacteria-Specific CD4(+) T Cells Identified by Activation-Induced Expression of CD154. J Immunol (2017) 0.75
Putative roles of a proline-glutamic acid-rich protein (PE3) in intracellular survival and as a candidate for subunit vaccine against Mycobacterium tuberculosis. Med Microbiol Immunol (2013) 0.75
MyD88 in Mycobacterium tuberculosis infection. Med Microbiol Immunol (2017) 0.75
Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with Mycobacterium tuberculosis following Isoniazid Therapy. Front Immunol (2017) 0.75
Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA (1999) 27.82
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med (2003) 24.99
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science (1999) 17.48
Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol (2003) 16.82
Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA (1994) 14.96
Immunology of tuberculosis. Annu Rev Immunol (2001) 14.26
Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med (1971) 11.44
Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol (1996) 10.26
Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A (2003) 9.15
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med (2003) 5.97
The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A (2003) 5.83
Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. J Infect Dis (2002) 5.15
M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell (2007) 4.90
Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc Natl Acad Sci U S A (2003) 4.64
ideR, An essential gene in mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun (2002) 4.54
Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J Exp Med (1983) 3.79
The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci U S A (2004) 3.63
The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biol (2001) 3.58
Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res (2008) 3.26
The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine (2006) 3.16
Autoreactivity by design: innate B and T lymphocytes. Nat Rev Immunol (2001) 3.08
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med (2009) 2.80
Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest (2007) 2.80
Advances in tuberculosis vaccine strategies. Nat Rev Microbiol (2006) 2.75
Secreted transcription factor controls Mycobacterium tuberculosis virulence. Nature (2008) 2.71
Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun (2009) 2.57
Global analysis of the Mycobacterium tuberculosis Zur (FurB) regulon. J Bacteriol (2006) 2.33
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J Bacteriol (2007) 2.31
Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci U S A (2009) 2.10
Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole. Infect Immun (2008) 2.05
A genetic screen for Mycobacterium tuberculosis mutants defective for phagosome maturation arrest identifies components of the ESX-1 secretion system. Infect Immun (2007) 1.98
Fatal disseminated Mycobacterium smegmatis infection in a child with inherited interferon gamma receptor deficiency. Clin Infect Dis (1997) 1.96
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine (2010) 1.88
Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun (2005) 1.81
Prolonged toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages. Infect Immun (2004) 1.75
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One (2009) 1.51
Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine (2005) 1.45
A unique Mycobacterium ESX-1 protein co-secretes with CFP-10/ESAT-6 and is necessary for inhibiting phagosome maturation. Mol Microbiol (2007) 1.44
Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens (2009) 1.41
Inhibition of major histocompatibility complex II expression and antigen processing in murine alveolar macrophages by Mycobacterium bovis BCG and the 19-kilodalton mycobacterial lipoprotein. Infect Immun (2004) 1.37
The ESX-5 secretion system of Mycobacterium marinum modulates the macrophage response. J Immunol (2008) 1.33
responses of mycobacterium tuberculosis to growth in the mouse lung. Infect Immun (2005) 1.31
Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production. PLoS Pathog (2008) 1.30
Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine (2005) 1.18
The 19-kD antigen and protective immunity in a murine model of tuberculosis. Clin Exp Immunol (2000) 1.12
Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice. Vaccine (2006) 1.01
Fatal pulmonary infection caused by Mycobacterium smegmetis in an infant. Indian J Pediatr (2000) 1.00
GLS/IL-12-modified Mycobacterium smegmatis as a novel anti-tuberculosis immunotherapeutic vaccine. Int J Tuberc Lung Dis (2009) 0.89
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Origins of highly mosaic mycobacteriophage genomes. Cell (2003) 9.78
Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology (2002) 6.20
The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A (2003) 5.83
Computational and experimental identification of C. elegans microRNAs. Mol Cell (2003) 5.22
Exploring the mycobacteriophage metaproteome: phage genomics as an educational platform. PLoS Genet (2006) 4.69
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature (2006) 4.59
Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol (2008) 4.31
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol (2002) 3.74
Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One (2009) 3.68
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood (2011) 3.41
Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood (2010) 3.35
Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nat Methods (2006) 3.32
GroEL1: a dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobacteria. Cell (2005) 3.23
Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A (2009) 3.19
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother (2005) 3.16
Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol (2006) 3.07
The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe (2008) 2.98
A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A (2008) 2.93
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol (2008) 2.90
A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med (2002) 2.87
Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A (2005) 2.83
Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med (2010) 2.82
Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness. Am J Respir Crit Care Med (2003) 2.82
Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest (2007) 2.80
Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis (2003) 2.79
Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol (2009) 2.74
Manufacturing and placing a bespoke support for the Marfan aortic root: description of the method and technical results and status at one year for the first ten patients. Interact Cardiovasc Thorac Surg (2009) 2.72
Para-inflammation in the aging retina. Prog Retin Eye Res (2009) 2.71
Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol (2004) 2.67
The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol (2007) 2.66
SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis. Mol Microbiol (2003) 2.62
TANGO1 facilitates cargo loading at endoplasmic reticulum exit sites. Cell (2009) 2.58
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol (2004) 2.56
Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat Immunol (2002) 2.54
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother (2007) 2.50
Roles of thermal adaptation and chemical ecology in Liriomyza distribution and control. Annu Rev Entomol (2009) 2.43
Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol (2011) 2.42
Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc Natl Acad Sci U S A (2002) 2.41
Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol (2010) 2.36
Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog (2007) 2.36
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med (2006) 2.35
Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol (2008) 2.35
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2009) 2.34
Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother (2003) 2.30
The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol (2007) 2.27
Cell population tracking and lineage construction with spatiotemporal context. Med Image Anal (2008) 2.26
Klf2 is an essential regulator of vascular hemodynamic forces in vivo. Dev Cell (2006) 2.26
Dynamics of macrophage cell populations during murine pulmonary tuberculosis. J Immunol (2003) 2.25
Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J (2007) 2.20
The effects of reactive nitrogen intermediates on gene expression in Mycobacterium tuberculosis. Cell Microbiol (2003) 2.20
Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis. PLoS Pathog (2009) 2.16
Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A (2010) 2.12
Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. Nat Med (2009) 2.12
Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice. Vaccine (2009) 2.12
A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells. Immunity (2011) 2.11
Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J Exp Med (2005) 2.10
A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog (2009) 2.09
Correcting motion artifacts in retinal spectral domain optical coherence tomography via image registration. Med Image Comput Comput Assist Interv (2009) 2.06
Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun (2003) 2.06
In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol (2002) 2.04
Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol (2003) 2.04
Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat Immunol (2003) 2.03
Noggin, retinoids, and fibroblast growth factor regulate hepatic or pancreatic fate of human embryonic stem cells. Gastroenterology (2010) 2.03
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A (2005) 2.03
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med (2010) 2.00
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity (2009) 2.00
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One (2011) 1.99
Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol (2002) 1.99
Improved tandem affinity purification tag and methods for isolation of protein heterocomplexes from plants. Plant J (2004) 1.99
A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat (2003) 1.98